false
0000027367
0000027367
2025-08-07
2025-08-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) August 7, 2025
Daxor
Corporation
(Exact
name of registrant as specified in its charter)
| New
York |
|
811-22684 |
|
13-2682108 |
| (State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
| 107
Meco Lane, Oak Ridge, TN |
|
37830 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
212-330-8500
Registrant’s
telephone number, including area code
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions ( see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b)
of the Act: |
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock $0.01 par value |
|
DXR |
|
Nasdaq |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Potential
persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
Item
8.01 – Other Events
Daxor
Corporation, the global leader in blood volume measurement technology, announces FDA 510(k) clearance for its next-generation rapid,
portable lab-based Blood Volume Analysis (BVA) system. The new Daxor BVA™ device quantifies a patient’s blood volume against
patient-specific norms, enabling precise care, significantly improving outcomes for millions of patients each year.
The
press release issued is attached to this filing as Exhibit 99.1
Item
9.01 Exhibits
| (d) | Exhibits.
The following exhibit is filed with this Current Report on Form 8-K: |
| No. | | Description |
| 99.1 | | Press release dated August
7, 2025 – Daxor Corporation Receives FDA Clearance for New Rapid, Portable Lab-Based
Blood Volume Analysis System |
| 104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
| |
DAXOR CORPORATION |
| |
(Registrant) |
| |
|
| Date:
August 7, 2025 |
By: |
/s/
Robert J. Michel |
| |
Name: |
Robert
J. Michel |
| |
Title: |
Chief
Financial Officer |
